Literature DB >> 23682386

The expression and clinical significance of Omi/Htra2 in hepatocellular carcinoma.

Zongquan Xu1, Xiaoping Chen, Cheng Peng, Enyu Liu, Yunguang Li, Changhai Li, Jun Niu.   

Abstract

BACKGROUND/AIMS: To investigate Omi/HtrA2 expression and its clinical significance in hepatocellular carcinoma.
METHODOLOGY: We analyzed Omi/HtrA2 expression in hepatocellular carcinoma, paracancerous tissues and normal hepatic tissues by immunohistochemistry, RT-PCR and Western blot. Hypoxia-inducible factor-1α (HIF-1α) expression was also detected in hepatocellular carcinoma samples by immunohistochemistry. Meanwhile, we retrospectively analyzed the relationship between Omi/HtrA2 expression and the survival times of the patients.
RESULTS: We found that Omi/HtrA2 overexpressed in hepatocellular carcinoma and was correlated with hepatocellular carcinoma differentiation, tumor size, portal vein invasion, clinical stage and lymph node metastasis. We also observed a significant inverse correlation between the expression of Omi,/HtrA2 and HIF-1α in hepatocellular carcinoma. The Kaplan-Meier estimates showed that patients who were Omi/HtrA2 positive had much longer survival times than those who were Omi/HtrA2 negative. Both univariate and multivariate analysis using the Cox regression model indicated that Omi/HtrA2 expression was a significant factor for prognosis.
CONCLUSIONS: Hepatocellular carcinoma cells may need Omi/HtrA2 expression for apoptosis and Omi/HtrA2 might be an important prognostic marker for primary hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23682386

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  5 in total

1.  Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.

Authors:  Hiroaki Soyama; Morikazu Miyamoto; Masashi Takano; Tadashi Aoyama; Hiroko Matsuura; Takahiro Sakamoto; Kazuki Takasaki; Mika Kuwahara; Kento Kato; Tomoyuki Yoshikawa; Hideki Iwahashi; Hitoshi Tsuda; Kenichi Furuya
Journal:  Med Oncol       Date:  2017-11-22       Impact factor: 3.064

2.  Cloning and Transcriptional Activity of the Mouse Omi/HtrA2 Gene Promoter.

Authors:  Dan Liu; Xin Liu; Ye Wu; Wen Wang; Xinliang Ma; Huirong Liu
Journal:  Int J Mol Sci       Date:  2016-01-16       Impact factor: 5.923

3.  The expression of HtrA2 and its diagnostic value in patients with hepatocellular carcinoma.

Authors:  Honggang Wang; Fuguo Jiang; Furong Hao; Ruixue Ju
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

4.  Role of ALDH1A1 and HTRA2 expression in CCL2/CCR2-mediated breast cancer cell growth and invasion.

Authors:  Qingting Hu; Megan Myers; Wei Fang; Min Yao; Gage Brummer; Justin Hawj; Curtis Smart; Cory Berkland; Nikki Cheng
Journal:  Biol Open       Date:  2019-06-28       Impact factor: 2.422

Review 5.  A review on the diagnosis and treatment of hepatocellular carcinoma with a focus on the role of Wnts and the dickkopf family of Wnt inhibitors.

Authors:  Junlin Shi; Jill M Keller; Jian Zhang; Evan T Keller
Journal:  J Hepatocell Carcinoma       Date:  2014-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.